Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003
Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Comparison of different dosage nebulised budesonide in COPD exacerbation Source: Annual Congress 2012 - COPD exacerbation Year: 2012
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
A digital inhaler uncovering patterns of SABA use in asthma and COPD Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020
Metered dose inhaler with spacer versus nebulizer in children with acute bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Source: Eur Respir J 2002; 19: 246-251 Year: 2002
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Preference for novel soft mist inhaler over pMDI in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Comparison of the effectiveness of parenteral and nebuliser steroid in COPD exacerbations Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Cost-effectiveness of budesonid/formoterol inhaler in treatment of moderate bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006